Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

And this time, it’s not just fringe actors fanning the flames. It’s policymakers. It’s media personalities. It’s individuals ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

The new variant, NB.1.8.1, is also a subvariant of the Omicron variant. It has spread rapidly, and the earliest sample of ...

At the start of an unprecedented meeting of vaccine committee of the US Centers for Disease Control and Prevention, the ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Sen. Cassidy voices concerns over new ACIP members' lack of expertise in microbiology and mRNA vaccines after the ousting of ...

A key vaccine advisory committee on Wednesday kicked off the first meeting of its newly installed lineup under a cloud of ...